HERMES: EFFECTS OF ZILTIVEKIMAB VERSUS PLACEBO ON MORBIDITY AND MORTALITY IN PATIENTS WITH HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION AND SYSTEMIC INFLAMMATION
- Registry ID
- EX6018-4915
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVO NORDISK CANADA INC
- Start date
- 2023-03-27
- Last update
- 2022-12-20
Conditions
- HEART FAILURE WITH PRESERVED EJECTION FRACTION
Related clinical trials
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF MARIDEBART CAFRAGLUTIDE ON MORTALITY AND
MORBIDITY IN PARTICIPANTS LIVING WITH HEART FAILURE WITH PRESERVED OR
MILDLY REDUCED EJECTION FRACTION AND OBESITY (MARITIME-HF)
- PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY AND
EFFICACY STUDY OF CDR132L ON REVERSE CARDIAC REMODELLING IN PARTICIPANTS WITH
HEART FAILURE WITH PRESERVED EJECTION FRACTION AND LEFT VENTRICULAR HYPERTROPHY
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF LEVOSIMENDAN IN PULMONARY HYPERTENSION PATIENTS WITH HEART FAILURE AND PRESERVED LEFT VENTRICULAR EJECTION FRACTION (PH-HFPEF): LEVEL: LEVOSIMENDAN TO IMPROVE EXERCISE LIMITATION IN PATIENTS WITH PH-HFPEF
- ATHENA: EFFECTS OF ZILTIVEKIMAB VERSUS PLACEBO ON HEART FAILURE SYMPTOMS AND PHYSICAL FONCTION I PATIENTS WITH HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION AND SYSTEMIC INFLAMMATION
- A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BMS-986435/MYK-224 IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3540378 IN ADULTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
View on source registry